Dermatology News and Research

Latest Dermatology News and Research

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

The North American Center for Continuing Medical Education, LLC , in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced several key sessions on the treatment of atrial fibrillation at the upcoming Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, to be held December 9-11, 2010, at the Washington Hilton in Washington, DC.

3 Nov 2010

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant Pharmaceuticals International, Inc. and Kadmon Pharmaceuticals LLC have concluded two strategic agreements for the development and commercialization of taribavirin and the commercial marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV).

1 Nov 2010

Allergan third quarter diluted loss per share increases to $2.21

Allergan, Inc. today announced operating results for the quarter ended September 30, 2010. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2010 to stockholders of record on November 10, 2010.

1 Nov 2010

Xstrahl launches new control system for X-ray therapy

Xstrahl, a designer and manufacturer of a world-renowned range of superficial and orthovoltage radiotherapy systems that have been essential in supporting healthcare professionals and their patients in over 500 clinics for the past 15 years, today announces the launch of Imperium, a new control system for its X-ray therapy system, at this year's ASTRO conference in San Diego, 31 October - 4 November.

From Xstrahl 1 Nov 2010

Valeant subsidiary to acquire leading skin care brands in Australia

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Biovail Laboratories International SRL (BLS), has agreed to acquire several privately–owned pharmacy skin care brands in Australia. The leading brands, including well-established local brands such as Hamilton's Suncare and Hamilton's Skin Therapy, are ranked #2 in suncare in the Australian pharmacy market.

29 Oct 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Miami Miller School receives grant to study impact of GenerationOne's mobile solution on heart failure patients

The James and Esther King Biomedical Research Program has awarded the University of Miami Miller School of Medicine Geriatrics Institute a $100,000 grant for a year-long study on the impact of GenerationOne's Mobile Heath Solution on heart failure patients.

29 Oct 2010

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced top-line results from ACCORD COPD II, a 12-week Phase III study comparing the efficacy and safety of inhaled aclidinium bromide, an investigative bronchodilator, to placebo in 544 patients with moderate to severe COPD.

29 Oct 2010

New nationwide initiative to conduct research on human immune system

A new nationwide research initiative has been launched to define changes in the human immune system's response to infection and vaccination using human rather than animal models, which could lead to better vaccines and other treatments. Baylor Research Institute (BRI), along with five other U.S.-based Human Immune Phenotyping Centers, will receive a total of $100 million over five years to conduct the research.

28 Oct 2010

IPC investigating relationship between BMI and severity of psoriasis in childhood

As people around the world get ready to participate in events for World Psoriasis Day on October 29, the International Psoriasis Council (IPC) is nearing completion with enrollment in a multi-center study on the relationship between obesity and psoriasis in children. The theme of this year’s World Psoriasis Day is childhood psoriasis.

28 Oct 2010

HRS to co-sponsor world's premier annual electrophysiology meeting

The North American Center for Continuing Medical Education, LLC in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced that the Electrophysiology Innovations Congress--EP Innovations 2010 will be co-sponsored by the Heart Rhythm Society. Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, will take place December 9-11, 2010, at the Washington Hilton in Washington, DC.

27 Oct 2010

Amgen reports $3,816 million for 2010 third quarter revenue

Amgen reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009.

26 Oct 2010

Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting

Revance Therapeutics, Inc. today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinum toxin type A which is under investigation for the treatment of lateral canthal lines (crow's feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago.

25 Oct 2010

New annual campaign to prevent skin cancer

The annual "Euromelanoma Day" campaign is designed to prevent skin cancer among the general public. While there has been considerable interest, it has proved difficult to reach out to some of the at-risk groups. As such, new ways of encouraging these people to go to a dermatologist are being introduced, reveals research from the University of Gothenburg presented at the dermatologist conference in Sweden.

25 Oct 2010

FDA approves LO LOESTRIN FE tablets for oral contraception

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy.

25 Oct 2010

Report finds shortage of Mass. physicians is getting worse

The Boston Herald: "The state's physician shortage is getting worse -- with many practices closed to new patients and a critical need for doctors in key specialties, according to a Massachusetts Medical Society report released today. ... The most acute need is for primary-care physicians who practice family or internal medicine. The study called the shortages in those two key areas 'critical.'

21 Oct 2010

Aqueous cream worsens eczema: Study

Researchers claim that a cream that is often used in a skin condition called eczema may actually make the condition worse. The research conducted at Bath University found that aqueous cream thinned the skin after a few weeks of use. They found that the cream contains a detergent rather than just moisturizers. The team also said that most GPs seemed unaware of official advice not to prescribe the cream as a moisturizer.

21 Oct 2010

FDA clears Burton Medical's AIM-200 O.R. for surgical lighting applications

Burton Medical, Inc., the leader in examination and minor surgery lighting equipment, has received FDA clearance for its AIM-200® O.R. light for surgical lighting applications in operating rooms for ambulatory surgical centers as well as acute care facilities.

21 Oct 2010

Z-Medica enters agreement with two Swedish medical device distributors for QuikClot products

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed exclusive distribution agreements with Vingmed AB and Mediplast AB, two leading Swedish medical device distributors, for distribution of its QuikClot line of hemostatic agents in Sweden, Denmark and Norway for the first time.

From Medica Corporation 21 Oct 2010